Indian Drug Innovation Moves From Generics to Global Research Model
According to the joint BCG‑Healthcoise analysis, Indian companies are no longer confined to generic and biosimilar products. Over 195 firms now hold a pipeline of 1,095 drug assets, many of which target international markets. The report highlights more than ten new molecular entities developed domestically, including the indigenous CRISPR‑based therapy BIRSA‑101 and the CAR‑T product NEXCAR‑19, whose price is roughly one‑tenth of comparable foreign treatments.